logo
logo
Search stocks & features
/
StocksStocks
Intraday BoosterIntraday Booster
Sector BoosterSector Booster
Stock ScreenerStock Screener
ScreenersScreeners
MoreMore

prime iconGo Prime
My PlansMy Plans
Privacy PolicyPrivacy Policy
ContactContact
Refer & EarnRefer & Earn
ScreenersScreeners
Main
Stock ScreenerStock Screener
Create ScreenerCreate Screener
Explore ScreenersExplore Screeners
Community ScreenersCommunity Screeners
Trading Screeners
CandleSticks ScreenerCandleSticks Screener
Top Gainers & LosersTop Gainers & Losers
Opening Range BreakoutOpening Range Breakout
Stock Screener AIStock Screener AI
Stock Quality ScorecardStock Quality Scorecard
Overvalued StocksOvervalued StocksNew
Undervalued StocksUndervalued StocksNew
Technical Screeners
EMA ScreenerEMA Screener
SMA ScreenerSMA Screener
WMA ScreenerWMA Screener
OHLC ScreenerOHLC Screener
Fibonacci ScreenerFibonacci Screener
VWAP ScreenerVWAP Screener
Pivot Point ScreenerPivot Point Screener
Overlay ScreenerOverlay Screener
Trend Indicator ScreenerTrend Indicator Screener
Volume Based Indicator ScreenerVolume Based Indicator Screener
Overbought/Sold ScreenerOverbought/Sold Screener
NR4 StocksNR4 Stocks
NR7 StocksNR7 Stocks
Previous Day High BreakoutPrevious Day High Breakout
Previous Day Low BreakoutPrevious Day Low Breakout
Previous Day Open BreakoutPrevious Day Open Breakout
Bullish Crossover StocksBullish Crossover Stocks
Bearish Crossover StocksBearish Crossover Stocks
High Volume ShockerHigh Volume Shocker
VWAP Breakout StocksVWAP Breakout Stocks
Range High BreakoutRange High Breakout
Range Low BreakoutRange Low Breakout
MoreMore
Markets
Global Market TodayGlobal Market Today
Global IndicesGlobal Indices
Indian IndicesIndian Indices
NIfty TodayNIfty Today
Advance Decline RatioAdvance Decline Ratio
Precious Metals
Gold Price TodayGold Price TodayNew
Silver Price TodaySilver Price TodayNew
Platinum Price TodayPlatinum Price TodayNew
Smart Money
FII DII DataFII DII DataNew
FII BuyingFII Buying
NSE Insider TradingNSE Insider Trading
SLB Stocks DataSLB Stocks Data
Sector BoosterSector Booster
Derivatives
FnO MovementsFnO Movements
NSE F&O Lot SizeNSE F&O Lot Size
Ban ListBan List
Analysis & Calendars
Technical DashboardTechnical Dashboard
Sector AnalysisSector AnalysisNew
Result CalendarResult Calendar
IPO CalendarIPO Calendar
Economic CalendarEconomic Calendar
Market openRefreshes 15sCloses in 4h 57m
Ipca Laboratories

Ipca Laboratories

NSE: IPCALABBSE 524494Health CarePharmaceuticalswww.ipca.com
View MapTV Chart
1,613.00
0.60−0.04%
DAY1,602
₹1,613.00
1,640
52W1,252
₹1,613.00
1,678
Open1,629.80
Prev Close1,613.60
Bid1,612.92100
Ask1,613.08100
Volume18.2K95%vs 20D avg
Market Cap₹40,958.01 Cr
Promoter Hold.44.7%
Face Value₹1
Fwd P/E31.9
PEG1.68
EV/EBITDA51.12
P/S4.07
ROA6.27%
Beta0.66
Div Payout29.53%
Valuation

Ipca Laboratories Ltd valuation: P/E, P/B and sector benchmarks.

Twelve years of multiples investors have paid for Ipca Laboratories Ltd, framed against the sector median so the premium or discount is obvious at a glance.

Ipca Laboratories Ltd trades at a P/E of 45.75× and P/B of 5.12×.

Key MetricsLive · as of 12 Jun 2026
the price tag

Valuation

Market Cap
₹40,958.01 Cr
P/E Ratio
watch45.75
P/B Ratio
avg4.57
EPS
32.78
the engine

Profitability

ROE
watch4.87%
ROCE
avg14.7%
Net Margin
avg8.89%
Op Margin
avg12.7%
the trajectory

Growth

EPS YoY
good25.77%
Revenue YoY
avg9.66%
Qtr Sales
good10.3%
Qtr Profit
good21.3%
the balance sheet

Financial Health

Debt / Equity
good0.2
Book Value
273.88
Div Yield
avg0.27%
Promoter Hold.
avg44.7%
Financials

Ipca Laboratories Ltd financials: P&L, balance sheet, cash flow, ratios.

Twelve years of audited numbers for Ipca Laboratories Ltd, switchable between annual and quarterly views, consolidated or standalone.

Ipca Laboratories Ltd reports its full P&L, balance sheet, cash flow and ratios on this page — current market capitalisation of ₹40,958.01 Cr and reported EPS of ₹32.78.

all values in ₹ Cr unless suffixed · source: company filings
Segment Analysis

Ipca Laboratories segment analysis: revenue and profit mix.

Disclosed business segments at Ipca Laboratories with their share of revenue and profit, switchable between consolidated and standalone reporting.

Ipca Laboratories discloses revenue and profit across multiple business segments — toggle between consolidated and standalone views to see the mix.

Segment-wise Financial Analysis

Investment Thesis

Ipca Laboratories Ltd investment thesis: bull case, bear case, and the flip lines.

Why someone would buy Ipca Laboratories Ltd, why someone wouldn't, and the quantitative tripwires that would force the call to flip.

Ipca Laboratories Ltd's investment case rests on 8 positive markers and 10 flagged concerns drawn from the latest reported filings.

bull case

What you're getting.

  • Ipca Laboratories boasts a healthy Return on Equity (ROE) of 12.8% and Return on Capital Employed (ROCE) of 14.7%, indicating efficient use of shareholder investments and strong operational profitability.

  • The company demonstrates robust quarterly performance with sales growth of 10.3% and a significant 21.3% increase in quarterly profit, showcasing consistent market demand and effective management.

  • Ipca Labs maintains a low debt-to-equity ratio of 0.20, suggesting a manageable debt burden and a strong financial foundation. This is further supported by a healthy operating profit margin (OPM) of 19.1%.

  • Consistent annual profit after tax of ₹895 crore highlights the company's sustained profitability. Additionally, DII holding increased to 36.45% in Sept 2025, reflecting growing institutional confidence.

  • The growing global demand for pharmaceutical products, driven by an aging population and increasing healthcare awareness, presents a significant market expansion opportunity for Ipca Laboratories.

bear case

What can break it.

  • The company's Price-to-Earnings (P/E) ratio of 36.50 is relatively high compared to peers like Cipla (23.65) and Dr Reddy's (18.09), potentially indicating the stock might be overvalued.

  • Recent stock price movements show some volatility and declines, with a wide 52-week range from ₹1168 to ₹1758, indicating potential market uncertainty and significant price fluctuations.

  • Promoter holding stands at 44.7%, which is below 50%. While stable, this leaves room for potential future dilution or shifts in control, which could impact long-term shareholder value.

  • Despite a low debt-to-equity ratio, the absolute debt of ₹1363 crore is substantial. This figure requires careful consideration within the context of the company's overall financial health.

  • Ipca's Return on Capital Employed (ROCE) of 14.7% is notably lower than several peers, such as Torrent Pharma (27.05%) and Zydus Lifesci (24.31%), suggesting room for efficiency improvement.

flip conditions

What would change my mind.

  • Trim if P/E re-rates above 59. The valuation cushion thins from there.

  • Reassess if quarterly profit growth prints below 0% for two consecutive quarters. The bull case relies on compounding earnings.

  • Watch interest coverage if debt-to-equity climbs above 1.00. Balance sheet risk re-prices growth multiples fast.

  • Exit if ROE slips below 8%. The operating engine is no longer compounding capital efficiently.

Shareholding

Ipca shareholding pattern: promoters, FII, DII and public.

Quarter-on-quarter ownership shifts in Ipca — who is buying, who is exiting, and which institutions hold the largest positions.

Shareholding Pattern

Loading shareholding data...

Peers

Ipca Laboratories Ltd peer comparison — same-sector benchmarks.

Same-sector listed peers ranked on P/E, market cap, dividend yield and growth — Ipca Laboratories Ltd is highlighted for quick read-across.

Quick Compare

Largest by Market Cap
Sun Pharmaceutical Industries Ltd
4.31L ₹ Cr
Best Profit Growth
Biofil Chemicals & Pharmaceuticals Ltd
1318.00 %
Highest Dividend Yield
Procter & Gamble Health Ltd
3.64 %

Peer Comparison

Company Name
AAREYDRUGS
Aarey Drugs & Pharmaceuticals Ltd
AARTIDRUGS
Aarti Drugs Ltd
AARTIPHARM
Aarti Pharmalabs Ltd
AJANTPHARM
Ajanta Pharma Ltd
AKUMS
Akums Drugs & Pharmaceuticals Ltd
ALBERTDAVD
Albert David Ltd
ALIVUS
Alivus Life Sciences Ltd
ALKEM
Alkem Laboratories Ltd
ALPA
Alpa Laboratories Ltd
AMRUTANJAN
Amrutanjan Health Care Ltd
APLLTD
Alembic Pharmaceuticals Ltd
ASTRAZEN
Astrazeneca Pharma India Ltd
AUROPHARMA
Aurobindo Pharma Ltd
BAFNAPH
Bafna Pharmaceuticals Ltd
BAJAJHCARE
Bajaj Healthcare Ltd
BALPHARMA
Bal Pharma Ltd
BIOCON
Biocon Ltd
BIOFILCHEM
Biofil Chemicals & Pharmaceuticals Ltd
BLISSGVS
Bliss GVS Pharma Ltd
BLUEJET
Blue Jet Healthcare Ltd
BROOKS
Brooks Laboratories Ltd
CAPLIPOINT
Caplin Point Laboratories Ltd
CIPLA
Cipla Ltd
COHANCE
Cohance Lifesciences Ltd
CONCORDBIO
Concord Biotech Ltd
DCAL
Dishman Carbogen Amcis Ltd
DIVISLAB
Divis Laboratories Ltd
DRREDDY
Dr Reddys Laboratories Ltd
EMCURE
Emcure Pharmaceuticals Ltd
ERIS
ERIS Lifesciences Ltd
FDC
FDC Ltd
GLAND
Gland Pharma Ltd
GLAXO
Glaxosmithkline Pharmaceuticals Ltd
GLENMARK
Glenmark Pharmaceuticals Ltd
GRANULES
Granules India Ltd
GUFICBIO
Gufic BioSciences Ltd
HALEOSLABS
Haleos Labs Limited
HESTERBIO
Hester Biosciences Ltd
HIKAL
Hikal Ltd
INDOCO
Indoco Remedies Ltd
INDSWFTLAB
Ind-Swift Laboratories Ltd
INNOVACAP
Innova Captab Ltd
IOLCP
IOL Chemicals & Pharmaceuticals Ltd
IPCALAB
Ipca Laboratories LtdCurrent Stock
JAGSNPHARM
Jagsonpal Pharmaceuticals Ltd
JBCHEPHARM
J B Chemicals & Pharmaceuticals Ltd
JUBLPHARMA
Jubilant Pharmova Ltd
KILITCH
Kilitch Drugs (India) Ltd
KOPRAN
Kopran Ltd
KREBSBIO
Krebs Biochemicals & Industries Ltd
LASA
Lasa Supergenerics Ltd
LAURUSLABS
Laurus Labs Ltd
LINCOLN
Lincoln Pharmaceuticals Ltd
LUPIN
Lupin Ltd
LYKALABS
Lyka Labs Ltd
MANGALAM
Mangalam Drugs and Organics Ltd
MANKIND
Mankind Pharma Ltd
MARKSANS
Marksans Pharma Ltd
MEDICAMEQ
Medicamen Biotech Ltd
MEDICO
Medico Remedies Ltd
MOREPENLAB
Morepen Laboratories Ltd
NATCOPHARM
Natco Pharma Ltd
NECLIFE
Nectar Lifescience Ltd
NEULANDLAB
Neuland Laboratories Ltd
NGLFINE
NGL Fine Chem Ltd
ONESOURCE
OneSource Specialty Pharma Ltd
ORCHPHARMA
Orchid Pharma Ltd
ORTINGLOBE
Ortin Global Ltd
PANACEABIO
Panacea Biotec Ltd
PFIZER
Pfizer Ltd
PGHL
Procter & Gamble Health Ltd
PPLPHARMA
Piramal Pharma Ltd
RPGLIFE
RPG Life Sciences Ltd
SAILIFE
Sai Life Sciences Ltd
SANOFI
Sanofi India Ltd
SANOFICONR
Sanofi Consumer Healthcare India Ltd
SENORES
Senores Pharmaceuticals Ltd
SHILPAMED
Shilpa Medicare Ltd
SIGACHI
Sigachi Industries Ltd
SMSPHARMA
SMS Pharmaceuticals Ltd
SOLARA
Solara Active Pharma Sciences Ltd
SPARC
Sun Pharma Advanced Research Company Ltd
STAR
Strides Pharma Science Ltd
SUNPHARMA
Sun Pharmaceutical Industries Ltd
SUPRIYA
Supriya Lifescience Ltd
SYNCOMF
Syncom Formulations (India) Ltd
THEMISMED
Themis Medicare Ltd
TORNTPHARM
Torrent Pharmaceuticals Ltd
UNICHEMLAB
Unichem Laboratories Ltd
VALIANTLAB
Valiant Laboratories Ltd
VENUSREM
Venus Remedies Ltd
VINEETLAB
Vineet Laboratories Ltd
VIYASH
Viyash Scientific Ltd
WANBURY
Wanbury Ltd
WINDLAS
Windlas Biotech Ltd
WOCKPHARMA
Wockhardt Ltd
ZIMLAB
Zim Laboratories Ltd
ZYDUSLIFE
Zydus Lifesciences Ltd
Technicals

Ipca Laboratories Ltd technical analysis: indicators, pivots and CPR.

Live RSI, MACD and moving-average signals plus today's pivot and Central Pivot Range levels for Ipca Laboratories Ltd — derived from the live tape, not yesterday's close.

Ipca Laboratories Ltd last traded at ₹1,613 with an intraday range of ₹1,602.2–₹1,640 — live indicator, pivot and CPR signals below.

Pivot points

Standard pivot — most widely referenced.

Pivot levels · Classic

Live: ₹1613.00
LevelPrice (₹)Distance% Δ
R41710.20+97.20+6.03%
R31672.40+59.40+3.68%
R21656.20+43.20+2.68%
R11634.60+21.60+1.34%
PIVOT1618.405.400.33%
CURRENT1613.00
S11521.20-91.80-5.69%
S21559.00-54.00-3.35%
S31580.60-32.40-2.01%
S41596.80-16.20-1.00%
CPR Levels
Support
Resistance
S4
S3
S2
S1
| CPR |
BC: 1615.70P: 1618.40TC: 1621.10
R1
R2
R3
R4
indicator
LTP: 1613.00
PDH: 1642.00
PDL: 1606.20
● Market Sentiment

IPCALAB is trading Below CPR, indicating Bearishness

● CPR Width

CPR is Average

● Opening Range

Day's range: 1617 ~ 1640

● Price Position

Trading Inside opening range

Delivery & Volume

Ipca Laboratories Ltd delivery volume — last 20 sessions of conviction.

Daily traded volume and delivery percentage for Ipca Laboratories Ltd over 20 sessions — the gap between intraday flipping and genuine accumulation.

Latest session delivery in Ipca Laboratories Ltd stood at 46.7% of traded volume, against a 20-day average of 50.7%.

Avg Delivery (20D)50.7%-4.0 ppt latest vs avg
Highest Delivery80.6%on 08 Jun
Avg Volume (20D)3.65 L20-day run-rate
Conviction Trend↑ Strengthening-4.0 ppt latest read
Volume & Delivery · last 20 sessions
Filings & Concalls

Ipca Laboratories announcements: results, concalls, ratings, M&A.

Filings Ipca Laboratories sent to the exchanges, sequenced as they hit the tape — concall transcripts, results, credit ratings and presentations.

Insider Activity

Ipca Laboratories insider trading: promoter and management activity.

Promoter, director and designated-employee transactions in Ipca Laboratories as reported to SEBI — buying and selling signals from the people who know the business best.

Ipca Laboratories insider activity below tracks 1 reported promoter, director and designated-employee transactions under SEBI Regulation 7(2).

InsiderCategoryTxn DateActionQuantityValue (₹)Price
Mrs. Usha M. ChandurkarInsider18 Dec 2024sell40.00 L₹599.7 Cr₹1,499.25
Corporate Actions

Ipca Laboratories dividend history, splits and bonus issues.

Every dividend, stock split and bonus issue Ipca Laboratories has declared, sequenced by announce and record date.

Ipca Laboratories corporate-action history below covers all declared dividends, stock splits and bonus issues recorded with NSE and BSE.

About the Company

About Ipca Laboratories Ltd: business, sector, key facts.

What Ipca Laboratories Ltd does, where it operates, the people running it, and the numbers that describe the entity behind the ticker.

Ipca Laboratories Ltd operates in the Pharmaceuticals industry under the Health Care sector, listed as NSE: IPCALAB, BSE: 524494.

IPCALAB
Pharmaceuticals

Ipca Laboratories Ltd

NSE · IPCALAB·BSE · 524494·www.ipca.com

Ipca Laboratories Limited is a multinational pharmaceutical company with a long history, established in 1949 and headquartered in Mumbai, India. The company operates across a broad global footprint, distributing its products to India, Europe, Africa, the Americas, Asia, the CIS region, and Australasia. Their business model is vertically integrated, encompassing both the manufacture and marketing of their products.

A significant portion of Ipca's business involves the production and sale of Active Pharmaceutical Ingredients (APIs). These APIs are key components in the creation of various medications and are provided for a wide range of therapeutic applications. Specifically, Ipca focuses on APIs for anti-hypertensive, anti-malarial, diuretic, DMARD (disease-modifying antirheumatic drug), and anthelmintic treatments. This focus on APIs demonstrates Ipca's commitment to supplying crucial components to the broader pharmaceutical industry.

In addition to APIs, Ipca manufactures and markets a diverse portfolio of both generic and branded pharmaceutical formulations. These formulations cover an extensive range of therapeutic areas, indicating a wide-ranging approach to healthcare needs. These areas include allergy, oncology (anti-neoplastic/cancer drugs), arthritis, epilepsy, cardiology, diabetes, dermatology, gastroenterology, hematology, infectious diseases, neurology, pain management (neuropathic pain and NSAIDs), ophthalmology, orthopedics, psychiatry, respiratory ailments, rheumatology, and urology. Furthermore, they also offer nutraceuticals and probiotics, expanding their reach into complementary health products.

Ipca's global reach is a key component of its business strategy. The company actively exports its products worldwide, showcasing its ability to compete and succeed in international markets. This international focus suggests a commitment to serving global healthcare needs and a capacity to adapt to diverse regulatory and market landscapes. The breadth of its product offerings, from APIs to a wide variety of formulations, positions Ipca to participate in numerous segments of the pharmaceutical market.

company facts
Founded / IPO23/02/1994
Employees17,335
SectorHealth Care
HeadquartersMumbai, MAHARASHTRA, IN
Market Cap₹40,958.01 Cr
Listed OnNATIONAL STOCK EXCHANGE OF INDIA
leadership29 on record
Shri. Premchand Godha
Executive Chairman of the Board
Mr. Pranay Godha
Chief Executive Officer, Managing Director, Executive Director
Mr. Ajit Jain
Chief Financial Officer, Managing Director, Executive Director
Mr. Pabitra Bhattacharya
President - Operations (API)
Mr. Sunil Ghai
President - Marketing
Dr. Sanjay Kapadia
President - Corporate Quality Assurance
Dr. Ashok Kumar
President - Research and Development (Chemicals)
Mr. Shailesh Laul
President - Operations (Formulations)
Mr. Hitesh Maheshwari
President - Research and Development (Formulations)
Mr. Shashil Mendonsa
President - International Marketing
Mr. Saidutta Nanda
President Human Resources
Dr. Anil Pareek
President - Medical Affairs and Clinical Research
§ ∞ · Plainly Answered

Questions investors ask about Ipca Laboratories Ltd (IPCALAB).

Quick answers grounded in this page's data — price action, fundamentals, ratios and ownership.

01What is the current share price of Ipca Laboratories Ltd (IPCALAB)?

The current share price of Ipca Laboratories Ltd (IPCALAB) is ₹1,613. Today, the stock has declined by ₹0.60 (0.04%), trading in a range of ₹1,602.2 to ₹1,640. The stock opened at ₹1,629.8 with a trading volume of 18,225 shares.

02Is Ipca Laboratories Ltd stock a good investment for long-term?

Ipca Laboratories Ltd can be considered for long-term investment based on several factors. The company has a market capitalization of ₹40,958.01 crores, P/E ratio of 45.75, ROE of 4.87%, and ROCE of 14.70%. The dividend yield stands at 0.27%. However, investment decisions should be based on your financial goals, risk appetite, and thorough research. It's recommended to consult with a SEBI-registered financial advisor before making investment decisions.

03What is the 52-week high and low price of Ipca Laboratories Ltd stock?

The 52-week high price of Ipca Laboratories Ltd (IPCALAB) is ₹1,678.3, while the 52-week low is ₹1,251.6. Currently trading at ₹1,613, the stock is 84.7% away from its 52-week low and 3.9% below its 52-week high. These levels help investors understand the stock's price volatility and trading range over the past year.

04Should I buy Ipca Laboratories Ltd stock at the current price?

Whether to buy Ipca Laboratories Ltd stock at ₹1,613 depends on multiple factors. The stock is currently trading with a P/E ratio of 45.75 and P/B ratio of N/A. Today's performance shows a loss of 0.04%. Consider analyzing the company's fundamentals, technical indicators, industry trends, and your investment horizon. Compare these metrics with industry peers and consult a financial advisor for personalized advice.

05What is the dividend yield of Ipca Laboratories Ltd and when is the next dividend?

Ipca Laboratories Ltd offers a dividend yield of 0.27%, which means for every ₹100 invested at the current price of ₹1,613, you can expect to receive approximately ₹0.27 annually as dividends. The face value of the stock is ₹1.00. For information about the next dividend announcement and ex-dividend date, please check the company's official announcements or visit the BSE/NSE websites.

06What are the key financial ratios and metrics of Ipca Laboratories Ltd?

Ipca Laboratories Ltd's key financial metrics include: P/E Ratio: 45.75, P/B Ratio: N/A, ROE: 4.87%, ROCE: 14.70%, Dividend Yield: 0.27%, EPS: ₹32.78, Book Value: ₹273.88, Debt-to-Equity: 0.20, and Current Ratio: N/A. The company's market cap stands at ₹40,958.01 crores. These metrics help evaluate the company's valuation, profitability, and financial health.

07How is Ipca Laboratories Ltd stock performing today in the market?

Ipca Laboratories Ltd stock opened at ₹1,629.8 and is currently trading at ₹1,613, showing a decline of ₹0.60 (0.04%). The intraday high is ₹1,640 and low is ₹1,602.2. The trading volume stands at 18,225 shares, indicating moderate market participation today.

08What is the P/E ratio of Ipca Laboratories Ltd and what does it indicate?

Ipca Laboratories Ltd has a Price-to-Earnings (P/E) ratio of 45.75, which means investors are willing to pay ₹45.75 for every ₹1 of earnings. With an EPS of ₹32.78, this P/E ratio suggests the stock may be trading at a premium, possibly due to high growth expectations. Compare this with industry peers and historical P/E ratios for better context.

Disclaimer

The data, ratios and commentary about Ipca Laboratories Ltd (IPCALAB) on this page are published for educational and informational purposes only and are not investment, legal or tax advice. StockeZee is not a SEBI-registered investment adviser, research analyst or portfolio manager, and no content here should be construed as a recommendation to buy, hold or sell any security. Live and historical market data may be delayed, revised by the exchanges, or contain errors; figures sourced from third-party feeds and corporate disclosures may not always be current. Past performance is not indicative of future results, and equity investments carry the risk of capital loss. Before acting on anything you read here, please consult a SEBI-registered financial advisor and read all scheme-related documents carefully.